New drug combo aims to wipe out hidden myeloma cells
NCT ID NCT06910124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding linvoseltamab to standard lenalidomide maintenance can eliminate remaining cancer cells in people with multiple myeloma. About 32 participants will receive the combination for up to 24 cycles. The goal is to see if this approach can deepen remission or bring back a no-cancer-cell state after relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linvoseltamab and lenalidomide
What this could lead to
If successful, this combination could help more multiple myeloma patients achieve a deep remission with no detectable cancer cells, potentially delaying relapse.
What could go wrong
This is a small, early-phase trial (32 participants) with no control group, so results may not apply broadly. Linvoseltamab can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact